source
- Artelo’s oral cannabinoid agonist matches semaglutide weight loss in obese mice, doubles effect when combinedArtelo Biosciences reported that its oral dual cannabinoid agonist, ART27.13, produced weight loss in diet‑induced obese mice that was comparable to the GLP‑1 receptor agonist semaglutide. In a fo…
- Novo Nordisk signs up to $1.4 billion deal with Orbis Medicines to develop oral macrocycle cardiometabolic drugsNovo Nordisk announced a partnership with Danish biotech Orbis Medicines, valued at up to $1.4 billion, to co-develop oral macrocycle drugs aimed at cardiometabolic diseases. The collaboration wil…BioSpace · 1mo agoDealPositive